首页 » 文章 » 文章详细信息
Journal of Immunology Research Volume 2020 ,2020-06-12
Hippocampal Atrophy in Systemic Lupus Erythematosus Patients without Major Neuropsychiatric Manifestations
Clinical Study
Shuang Liu 1 , 2 Yuqi Cheng 2 , 3 Yueyin Zhao 1 Aiyun Lai 1 Zhaoping Lv 1 Zhongqi Xie 1 Bibhuti Upreti 1 Xiangyu Wang 1 Xiufeng Xu 3 Chunrong Luo 4 Hongjun Yu 4 Baoci Shan 5 Lin Xu 6 Jian Xu 1 , 2
Show affiliations
DOI:10.1155/2020/2943848
Received 2020-03-13, accepted for publication 2020-05-21, Published 2020-06-12
PDF
摘要

This study was conducted to explore hippocampal structural changes and their possible associations with clinical characteristics, emotional status, and treatment regimens in patients with systemic lupus erythematosus (SLE) without major neuropsychiatric manifestations (non-NPSLE). Eighty-five non-NPSLE patients with normal conventional magnetic resonance imaging (MRI) and seventy-seven matched healthy control (HC) subjects were recruited. All participants underwent the standard high-resolution volumetric MRI. The bilateral hippocampal volume (HIPV) and hippocampal density (HIPD) were calculated, respectively, for each participant. We found that the bilateral HIPV and HIPD of the SLE patient group were significantly less than those of the HC group. The bilateral HIPV of female patients were significantly less than those of male patients. The SLE disease activity index (SLEDAI) was negatively correlated with the bilateral HIPV and the right HIPD. Urine protein quantity was negatively correlated with the bilateral HIPV and HIPD. Hydroxychloroquine (HCQ) showed a protective effect on right HIPV. In conclusion, we found that the early hippocampal atrophy could occur before obvious neuropsychiatric manifestations and might be associated with SLE disease activity and organ damages. Early detection and intervention of hippocampal damage might prevent the progression to NPSLE. More studies are needed to fully understand the underlying mechanisms of hippocampal atrophy in SLE.

授权许可

Copyright © 2020 Shuang Liu et al. 2020
This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

通讯作者

Jian Xu.Department of Rheumatology and Immunology, First Affiliated Hospital of Kunming Medical University, Kunming 650032, China, kmmc.cn;Yunnan Key Laboratory of Laboratory Medicine, Kunming 650032, China.casxujian@163.com

推荐引用方式

Shuang Liu,Yuqi Cheng,Yueyin Zhao,Aiyun Lai,Zhaoping Lv,Zhongqi Xie,Bibhuti Upreti,Xiangyu Wang,Xiufeng Xu,Chunrong Luo,Hongjun Yu,Baoci Shan,Lin Xu,Jian Xu. Hippocampal Atrophy in Systemic Lupus Erythematosus Patients without Major Neuropsychiatric Manifestations. Journal of Immunology Research ,Vol.2020(2020)

您觉得这篇文章对您有帮助吗?
分享和收藏
0

是否收藏?

参考文献
[1] J. Xu, Y. Cheng, P. Chai, Z. Lu. et al.(2010). White-matter volume reduction and the protective effect of immunosuppressive therapy in systemic lupus erythematosus patients with normal appearance by conventional magnetic resonance imaging. The Journal of Rheumatology.37(5):974-986. DOI: 10.1136/annrheumdis-2013-205139.
[2] S. Appenzeller, G. B. Pike, A. E. Clarke. (2008). Magnetic resonance imaging in the evaluation of central nervous system manifestations in systemic lupus erythematosus. Clinical Reviews in Allergy and Immunology.34(3):361-366. DOI: 10.1136/annrheumdis-2013-205139.
[3] T. Bartsch, P. Wulff. (2015). The hippocampus in aging and disease: from plasticity to vulnerability. Neuroscience.309:1-16. DOI: 10.1136/annrheumdis-2013-205139.
[4] M. B. Lauvsnes, M. K. Beyer, J. T. Kvaløy, O. J. Greve. et al.(2014). Association of hippocampal atrophy with cerebrospinal fluid antibodies against the NR2 subtype of the N-methyl-D-aspartate receptor in patients with systemic lupus erythematosus and patients with primary Sjögren's syndrome. Arthritis & Rhematology.66(12):3387-3394. DOI: 10.1136/annrheumdis-2013-205139.
[5] S. Appenzeller, A. D. Carnevalle, L. M. Li, L. T. L. Costallat. et al.(2006). Hippocampal atrophy in systemic lupus erythematosus. Annals of the Rheumatic Diseases.65(12):1585-1589. DOI: 10.1136/annrheumdis-2013-205139.
[6] J. Xu, Y. Cheng, A. Lai, Z. Lv. et al.(2015). Autoantibodies affect brain density reduction in nonneuropsychiatric systemic lupus erythematosus patients. Journal of Immunology Research.2015-920711. DOI: 10.1136/annrheumdis-2013-205139.
[7] N. Costedoat-Chalumeau, B. Dunogué, N. Morel, V. le Guern. et al.(2014). Hydroxychloroquine: a multifaceted treatment in lupus. Presse Médicale.43(6):e167-e180. DOI: 10.1136/annrheumdis-2013-205139.
[8] E. Trysberg, H. Carlsten, A. Tarkowski. (2016). Intrathecal cytokines in systemic lupus erythematosus with central nervous system involvement. Lupus.9(7):498-503. DOI: 10.1136/annrheumdis-2013-205139.
[9] R. L. Brey. (2007). Neuropsychiatric lupus: clinical and imaging aspects. Bulletin of the NYU Hospital for Joint Diseases.65(3):194-199. DOI: 10.1136/annrheumdis-2013-205139.
[10] E. Kozora, M. S. Brown, C. M. Filley, L. Zhang. et al.(2010). Memory impairment associated with neurometabolic abnormalities of the hippocampus in patients with non-neuropsychiatric systemic lupus erythematosus. Lupus.20(6):598-606. DOI: 10.1136/annrheumdis-2013-205139.
[11] D. D. Gladman, D. Ibañez, M. B. Urowitz. (2002). Systemic lupus erythematosus disease activity index 2000. The Journal of Rheumatology.29(2):288-291. DOI: 10.1136/annrheumdis-2013-205139.
[12] N. J. Abbott, L. L. F. Mendonça, D. E. M. Dolman. (2016). The blood-brain barrier in systemic lupus erythematosus. Lupus.12(12):908-915. DOI: 10.1136/annrheumdis-2013-205139.
[13] L. A. González, G. J. Pons-Estel, J. Zhang, L. M. Vilá. et al.(2009). Time to neuropsychiatric damage occurrence in LUMINA (LXVI): a multi-ethnic lupus cohort. Lupus.18(9):822-830. DOI: 10.1136/annrheumdis-2013-205139.
[14] C. Kowal, L. A. DeGiorgio, T. Nakaoka, H. Hetherington. et al.(2004). Cognition and Immunity: Antibody Impairs Memory. Immunity.21(2):179-188. DOI: 10.1136/annrheumdis-2013-205139.
[15] I. Shapira-Lichter, E. Vakil, I. Litinsky, N. Oren. et al.(2013). Learning and memory-related brain activity dynamics are altered in systemic lupus erythematosus: a functional magnetic resonance imaging study. Lupus.22(6):562-573. DOI: 10.1136/annrheumdis-2013-205139.
[16] R. C. Oldfield. (1971). The assessment and analysis of handedness: the Edinburgh inventory. Neuropsychologia.9(1):97-113. DOI: 10.1136/annrheumdis-2013-205139.
[17] D. A. Ballok, J. Woulfe, M. Sur, M. Cyr. et al.(2004). Hippocampal damage in mouse and human forms of systemic autoimmune disease. Hippocampus.14(5):649-661. DOI: 10.1136/annrheumdis-2013-205139.
[18] G. Ruiz-Irastorza, M. Ramos-Casals, P. Brito-Zeron, M. A. Khamashta. et al.(2009). Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review. Annals of the Rheumatic Diseases.69(1):20-28. DOI: 10.1136/annrheumdis-2013-205139.
[19] T. W. J. Huizinga, S. C. A. Steens, M. A. van Buchem. (2001). Imaging modalities in central nervous system systemic lupus erythematosus. Current Opinion in Rheumatology.13(5):383-388. DOI: 10.1136/annrheumdis-2013-205139.
[20] G. Sanna, M. Piga, J. W. Terryberry, M. T. Peltz. et al.(2016). Central nervous system involvement in systemic lupus erythematosus: cerebral imaging and serological profile in patients with and without overt neuropsychiatric manifestations. Lupus.9(8):573-583. DOI: 10.1136/annrheumdis-2013-205139.
[21] R. F. van Vollenhoven, M. Mosca, G. Bertsias, D. Isenberg. et al.(2014). Treat-to-target in systemic lupus erythematosus: recommendations from an international task force. Annals of the Rheumatic Diseases.73(6):958-967. DOI: 10.1136/annrheumdis-2013-205139.
[22] D. C. Adelman, E. Saltiel, J. R. Klinenberg. (1986). The neuropsychiatric manifestations of systemic lupus erythematosus: an overview. Seminars in Arthritis and Rheumatism.15(3):185-199. DOI: 10.1136/annrheumdis-2013-205139.
[23] B. Diamond, B. T. Volpe. (2012). A model for lupus brain disease. Immunological Reviews.248(1):56-67. DOI: 10.1136/annrheumdis-2013-205139.
[24] J. Zhang, A. M. Jacobi, T. Wang, R. Berlin. et al.(2009). Polyreactive autoantibodies in systemic lupus erythematosus have pathogenic potential. Journal of Autoimmunity.33(3-4):270-274. DOI: 10.1136/annrheumdis-2013-205139.
[25] O. Grimm, S. Pohlack, R. Cacciaglia, T. Winkelmann. et al.(2015). Amygdalar and hippocampal volume: a comparison between manual segmentation, Freesurfer and VBM. Journal of Neuroscience Methods.253:254-261. DOI: 10.1136/annrheumdis-2013-205139.
[26] E. Kozora, D. B. Arciniegas, C. M. Filley, M. C. Ellison. et al.(2005). Cognition, MRS neurometabolites, and MRI volumetrics in non-neuropsychiatric systemic lupus erythematosus: preliminary data. Cognitive and Behavioral Neurology.18(3):159-162. DOI: 10.1136/annrheumdis-2013-205139.
[27] M. Bravo-Zehnder, E. M. Toledo, F. Segovia-Miranda, F. G. Serrano. et al.(2015). Anti-ribosomal P protein autoantibodies from patients with neuropsychiatric lupus impair memory in mice. Arthritis & Rhematology.67(1):204-214. DOI: 10.1136/annrheumdis-2013-205139.
[28] T. Ren, R. C. M. Ho, A. Mak. (2012). Dysfunctional cortico-basal ganglia-thalamic circuit and altered hippocampal-amygdala activity on cognitive set-shifting in non-neuropsychiatric systemic lupus erythematosus. Arthritis and Rheumatism.64(12):4048-4059. DOI: 10.1136/annrheumdis-2013-205139.
[29] G. E. Gillies, S. McArthur. (2010). Estrogen actions in the brain and the basis for differential action in men and women: a case for sex-specific medicines. Pharmacological Reviews.62(2):155-198. DOI: 10.1136/annrheumdis-2013-205139.
[30] F. K. Leung, P. R. Fortin. (2003). Intravenous cyclophosphamide and high dose corticosteroids improve MRI lesions in demyelinating syndrome in systemic lupus erythematosus. The Journal of Rheumatology.30(8):1871-1873. DOI: 10.1136/annrheumdis-2013-205139.
[31] M. C. Hochberg. (1997). Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis and Rheumatism.40(9):1725. DOI: 10.1136/annrheumdis-2013-205139.
[32] H. X. Gao, S. R. Campbell, M. H. Cui, P. Zong. et al.(2009). Depression is an early disease manifestation in lupus-prone MRL/lpr mice. Journal of Neuroimmunology.207(1-2):45-56. DOI: 10.1136/annrheumdis-2013-205139.
[33] S. Liu, Y. Cheng, Y. Zhao, H. Yu. et al.(2018). Clinical factors associated with brain volume reduction in systemic lupus erythematosus patients without major neuropsychiatric manifestations. Frontiers in Psychiatry.9:8. DOI: 10.1136/annrheumdis-2013-205139.
[34] C. Bombardier, D. D. Gladman, M. B. Urowitz, D. Caron. et al.(1992). Derivation of the SLEDAI. A disease activity index for lupus patients. Arthritis and Rheumatism.35(6):630-640. DOI: 10.1136/annrheumdis-2013-205139.
[35] K. Baraczka, K. Nékám, T. Pozsonyi, I. Szüts. et al.(2004). Investigation of cytokine (tumor necrosis factor-alpha, interleukin-6, interleukin-10) concentrations in the cerebrospinal fluid of female patients with multiple sclerosis and systemic lupus erythematosus. European Journal of Neurology.11(1):37-42. DOI: 10.1136/annrheumdis-2013-205139.
[36] E. Wenger, J. Mårtensson, H. Noack, N. C. Bodammer. et al.(2014). Comparing manual and automatic segmentation of hippocampal volumes: reliability and validity issues in younger and older brains. Human Brain Mapping.35(8):4236-4248. DOI: 10.1136/annrheumdis-2013-205139.
文献评价指标
浏览 41次
下载全文 0次
评分次数 0次
用户评分 0.0分
分享 0次